BioMarin Pharmaceutical, Inc.

BioMarin Pharmaceutical, Inc. is a Humankind 100 company whose ranking is based on its Humankind Value, a proprietary metric that provides an estimate of the overall dollar amount a company creates for investors, consumers, employees, and society at large.

BioMarin Pharmaceutical Inc. is an American biotechnology company specializing in developing therapies for genetic diseases. Their research into enzyme replacement therapies has led to BioMarin becoming a leader in treating rare ailments.

Ticker: BMRN

Humankind Value: $25.9 B

Revenue: $1.7 B

Market Cap: $15.0 B

(All values are in US Dollars, where M=Million, B=Billion, T=Trillion.)

Healthcare is a central component of our measure of Humankind Value, as a large contribution to modern life expectancies has come from the last 150 years of medical innovation. The greatest contributors to BioMarin’s positive Humankind Value are Healthcare R&D ($20.2 B), Pharmaceuticals ($5.3 B), and Economic Value ($411.1 M). Positive value from Healthcare R&D and Pharmaceuticals contains our estimation of 528,835.1 additional years lived by people worldwide. It adds economic value by offering to consumers goods and services that they value, paying employees for their labor in producing these goods and services, and providing value for shareholders. The Humankind Value of this company can improve with reductions in Greenhouse Gases (-$127.7 M) and Air Pollution (-$26.0 M). Healthcare R&D, Pharmaceuticals, Economic Value, Greenhouse Gases, and Air Pollution are attached to this company as a result of its direct business activities.

How the Humankind Value Methodology Drives the Rankings

We take a quantitative, data-driven approach to estimating the economic impact that companies have on investors, customers, employees, and society at large, rolling social responsibility into a single dollar value that we use to represent what a company is contributing to humanity. As far as we can tell, we're the first ones doing it this way.

LEARN MORE ABOUT OUR RESEARCH
How Methodology Drives the Rankings